Literature DB >> 14738462

Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes.

M Füchtenbusch1, E Bonifacio, V Lampasona, A Knopff, A-G Ziegler.   

Abstract

Pregnancy is a natural state of immunoprotection and tolerance. We studied subjects with gestational diabetes (GDM) to evaluate the influence of pregnancy on the humoral immune response to the autoantigen GAD and to injected insulin. Antibodies against glutamic acid decarboxylase (GADA) subclasses and epitope reactivity were determined in 34 GADA-positive pregnant patients with GDM, in 20 GADA-positive relatives of people with TID and in 25 GADA-positive patients with newly diagnosed TID. Partum levels of insulin antibodies (IA), IgG1- and IgG4-IA were measured in 131 women with GDM treated with human insulin from the time of diabetes diagnosis (including 22 with GADA) and were compared to 19 patients with TID after 3 months of insulin treatment. GADA titre and subclasses were similar among all groups. GADA in GDM patients bound fewer epitopes than GADA in relatives of patients with TID (all epitopes being present in 23%versus 65%, P < 0.01). In particular, antibodies to the minor GADA epitopes GAD6596-249, GAD651-100 and GAD67 were less frequent in patients with GDM compared to relatives (P < 0.01). Antibodies to insulin (IA) were found in 17% of patients with GDM. They were more frequent in GDM patients with GADA compared to GADA-negative patients (41%versus 12%, P < 0.005). IgG1 was the dominant insulin antibody subclass response in both patients with GDM and TID but levels of IgG1-IA and IgG4-IA were significantly lower in patients with GDM compared to patients with TID (P < 0.004). Antibody responses in women with gestational diabetes appear to be dampened and restricted, but without change in subclass usage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738462      PMCID: PMC1808948          DOI: 10.1111/j.1365-2249.2004.02355.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes.

Authors:  M Balsells; R Corcoy; D Mauricio; J Morales; A García-Patterson; G Carreras; M Puig-Domingo; A de Leiva
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

2.  Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

Authors:  T Tuomi; A Carlsson; H Li; B Isomaa; A Miettinen; A Nilsson; M Nissén; B O Ehrnström; B Forsén; B Snickars; K Lahti; C Forsblom; C Saloranta; M R Taskinen; L C Groop
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

3.  GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.

Authors:  J Dittler; D Seidel; M Schenker; A G Ziegler
Journal:  Diabetes       Date:  1998-04       Impact factor: 9.461

4.  Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study.

Authors:  M Füchtenbusch; K Ferber; E Standl; A G Ziegler
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

5.  Low prevalence of islet autoantibodies in patients with gestational diabetes mellitus.

Authors:  N Dozio; A Beretta; C Belloni; M Castiglioni; S Rosa; E Bosi; E Bonifacio
Journal:  Diabetes Care       Date:  1997-01       Impact factor: 19.112

6.  Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality.

Authors:  M I Hawa; D Fava; F Medici; Y J Deng; A L Notkins; G De Mattia; R D Leslie
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

7.  Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens.

Authors:  M Füchtenbusch; K Kredel; E Bonifacio; O Schnell; A G Ziegler
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

8.  IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens.

Authors:  E Bonifacio; V Lampasona; P J Bingley
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

9.  Gestational diabetes mellitus: evidence for autoimmunity against the pancreatic beta cells.

Authors:  R C McEvoy; B Franklin; F Ginsberg-Fellner
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

10.  Prevalence and predictive value of islet cell antibodies and insulin autoantibodies in women with gestational diabetes.

Authors:  P Damm; C Kühl; K Buschard; B K Jakobsen; A Svejgaard; F Sodoyez-Goffaux; M Shattock; G F Bottazzo; L Mølsted-Pedersen
Journal:  Diabet Med       Date:  1994-07       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.